|Trial status||Trial open for recruitment|
Prospective observational study
|Inclusion criteria||patients that have initiated reimbursed ibrutinib therapy on or after its launch (via the eHealth procedure) or participated in the Medical Need Program for CLL or MCL and switched to reimbursed ibrutinib on or after 1 August 2015 or had started treatment|
The new Institut Jules Bordet, a building for the practice of medical excellence now and in the future. Meeting at the end of November 2021 on the ULB campus in Anderlecht.